​

Pfizer made the decision to stop further development and marketing of this gene therapy for Hemophilia B in all world markets. The decision was primarily due to low patient demand or interest in any of the hemophilia gene therapies. The company is committed to supporting patients who have already received Beqvez as part of clinical trials. Pfizer will now focus on alternative therapies, including its approved treatment, Hympavzi. Pfizer has exited the  gene therapy market as they backed away from further research on the other clinical trials they had in process for Duchenne Muscular Dystrophy and Hemophilia A.